Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03236844 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy Participants
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 114
- Enrollment target
NCT03236844 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 114 participants.
The verdict
NCT03236844, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 114 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the relative bioavailability of the high concentration liquid formulation (HCLF) of gantenerumab produced with the G4 process in comparison to the same HCLF of gantenerumab produced with the G3 process in healthy participants following single SC dose administration.
Interventions
- DRUG Gantenerumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2017-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03236844
The ClinicalTrials.gov registry entry for NCT03236844 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gantenerumab is the first listed.
NCT03236844 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03236844 about?
NCT03236844 is a clinical study titled "Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy Participants". The purpose of this study is to assess the relative bioavailability of the high concentration liquid formulation (HCLF) of gantenerumab produced with the G4 process in comparison to the same HCLF of gantenerumab produced with the G3 process in healthy participants following single SC dose administra...
What is the current status of trial NCT03236844?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 114 participants. The study started on 2017-08-01. Estimated completion is 2017-12-15.
What interventions are being tested in trial NCT03236844?
The interventions under investigation include: Gantenerumab (DRUG).
Who is sponsoring clinical trial NCT03236844?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.